Pellucid marginal degeneration (PMD) is an eye condition that has been around for a long time, but is still relatively unknown and poorly understood. PMD is a progressive, non-inflammatory condition that causes thinning of the cornea at the outer edge, or margin, of the eye. This can lead to decreased vision, light sensitivity, and other vision-related problems. The exact cause of PMD is unknown, but it is thought to be related to genetics, environmental factors, or a combination of both. In this article, we will explore the mysteries of PMD, discuss the symptoms, diagnosis, and treatment options, and provide an overview of the current research.
Pellucid marginal degeneration (PMD) is a progressive, non-inflammatory eye disease that affects the peripheral cornea. It is characterized by thinning of the cornea at the outer edge, or margin, of the eye. This thinning can cause decreased vision, light sensitivity, and other vision-related problems. PMD is most commonly seen in people between the ages of 20 and 40, although it can occur at any age.
The most common symptom of PMD is decreased vision in the affected eye. This can range from mild to severe, depending on the severity of the condition. Other symptoms may include light sensitivity, glare, halos around lights, double vision, and astigmatism. In some cases, the condition may also cause pain or discomfort.
PMD is typically diagnosed during a comprehensive eye exam. During the exam, the doctor will look for signs of thinning of the cornea at the outer edge of the eye. They may also use a slit lamp to examine the cornea more closely. Imaging tests, such as OCT (optical coherence tomography) or ultrasound, may also be used to confirm the diagnosis.
Treatment of PMD is aimed at relieving symptoms and preserving vision. In most cases, this can be done with glasses, contact lenses, or surgery. In severe cases, corneal transplantation may be necessary.
Currently, there is limited research on PMD, and the exact cause of the condition is unknown. However, researchers believe that genetics, environmental factors, or a combination of both may play a role. Studies have also suggested that PMD may be associated with certain autoimmune diseases, such as rheumatoid arthritis.
Pellucid marginal degeneration is a progressive, non-inflammatory eye condition that can cause decreased vision, light sensitivity, and other vision-related problems. Although the exact cause of PMD is unknown, it is thought to be related to genetics, environmental factors, or a combination of both. Treatment of PMD is aimed at relieving symptoms and preserving vision, and can include glasses, contact lenses, or surgery. Research on PMD is ongoing, and further studies are needed to better understand the condition and develop more effective treatments.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
1.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation